Don't blame pharma for weak psychiatric drug pipeline

08/22/2013 | Forbes

Timidness on the part of the pharmaceutical industry is not the reason for a weak pipeline of psychiatric treatments, John LaMattina writes. Drugmakers are not afraid of investing in costly drug studies, but they lack compelling targets and face high hurdles to reach market, LaMattina writes. The best hope for boosting pipelines may be the Brain Activity Map project and other research that sheds light on the mechanisms related to mental illness, he writes.

View Full Article in: